Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 27;16:550. doi: 10.1186/s12885-016-2598-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — MK-2206 sensitizes BRCA2 mutants to cisplatin and olaparib therapy. a 1. PEO1 and PEO4 cells were treated with various concentrations of cisplatin, MK-2206, or both in combination at a constant 1:1 ratio. After 72 h, MTS solution was added and absorbance read at 490 nm after 4 h. Data are means ± SD. 2. CI values were calculated for the drug combination of cisplatin and MK-2206 at each concentration. 3. PEO1 and PEO4 cells were treated with increasing doses of cisplatin in combination with 1 μM MK-2206 and caspase 3/7 activity determined after 72 h. b 1. Assay repeated for the combination of olaparib and MK-2206. 2. CI values for olaparib and MK-2206 3. a. Caspase 3/7 activity assay for olaparib and MK-2206 (1 μM) . Asterisks, p < 0.05 (Student’s t-test) b Caspase 3/7 activity assay for olaparib and MK-2206 (1, 3, and 6 μM)